The transformative journey of eXmoor Pharma has reached a pivotal moment with the recent acquisition of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone
The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and
Recent tensions between the United States and China have extended into the biotech and pharmaceutical sectors, sparking bipartisan calls for increased regulatory scrutiny. At the heart of the matter: clinical trials conducted by U.S. pharmaceutical companies in collaboration with Chinese
Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and
In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,
In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These
